Twitter Facebook Linked In Zone In Google Plus 
June 2018 Research Update

Post-transcriptional Gene Silencing Goes Nuclear

Recently, researchers in France identified a novel protein that controls post-transcriptional gene silencing. Their finding is significant because it is the first-time post-transcriptional silencing has included nucleoplasmic mechanisms.

The researchers stumbled upon this finding while trying to understand how microRNA (miRNA) targets and modulates RNA degradation.

Traditional methods to identify miRNA binding sites have been shown to produce approximately 70% false or negative targets, so Bottini and colleagues decided to circumvent this problem by identifying RNA binding proteins that bind to messenger RNAs (mRNAs) to control miRNA targeting.

"In support of this mechanism, it has been shown that some RNA-binding proteins associate with specific mRNAs and interfere with specific miRNA-binding sites to either inhibit or enhance miRNA targeting. This result leads to the concept of a sequence microenvironment surrounding miRNA-binding sites that plays an important role in regulating miRNA activity," the authors explain...

Read More
Our mRNA is Setting the Standard for Quality and Performance
TriLink's portfolio of catalog and custom synthesis mRNA has set the standard for quality and performance with our proprietary CleanCap™ Technology which enhances and achieves superior translation.
Come and See Us
RNA Therapeutics Conference
From Base Pairs to Bedsides
June 28-29 Worcester, MA
Schedule a meeting
Get instant pricing & ordering for modified and standard oligos from 0.2 µmole to 15 µmole synthesis scales.
Oligos for IVD & Molecular Dx

TriLink diagnostic oligo products include robust DNA and RNA modification options, providing our diagnostic customers with a variety of specialized conjugates. We understand that diagnostic medical device technologies require diverse oligo modifications at different scales of synthesis. Our expertise and extensive selection of modifications and conjugates ensure that we can meet your molecular diagnostic oligonucleotide synthesis requirements.

Diagnostics Oligo Catagories We Offer:

  • Research Oligos are synthesized using the same chemistry and reagents as our Diagnostic Oligos. The cost and turnaround time are reduced due to a smaller synthesis scale.
  • Pilot Oligos provide an important step towards commercialization. These are produced in the cGMP lab suites under a drafted fully traceable batch record.
  • Diagnostic Oligos are used for in vitro diagnostics (IVD), laboratory developed tests (LDT) under CLIA, and analyte specific reagents (ASR). Use of these oligos includes clinical trial performance validation and post-launch diagnostic test manufacturing.
Learn More
Ask An Expert

Do I need to have my oligonucleotide purified? If so, what method is best?

The need for oligo purification is dependent on a number of factors, including your application and oligo complexity. HPLC and PAGE are the most common purification methods. Reverse phase HPLC (RP-HPLC) is by far the most common, and is very useful in separating dye-labeled from unlabeled oligos...

Read More
Zone In With The Zon Blog Post

June Is Acute Myeloid Leukemia (AML) Awareness Month

• N6 Methylation of Adenosine in mRNA by METTL3 Linked to AML

• Linking METTL3 to AML by Gene Knockdown with RNA Interference

• Targeting METTL3 May Lead to a New Drug for AML

View Blog Post


© 2018 TriLink BioTechnologies | All Rights Reserved